Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
304 Leser
Artikel bewerten:
(0)

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 24 February 2017 - The Annual General Meeting of Novo Nordisk A/S will be held on:

Thursday 23 March 2017 at 2.00 pm (CET)

at Bella Center, entrance West, Center Boulevard 5, 2300 Copenhagen S, Denmark.

The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Principles, is enclosed.

BOARD OF DIRECTORS - PROPOSED CHANGES IN COMPOSITION

All board members elected by the Annual General Meeting are up for election. Bruno Angelici does not seek re-election as member of the Board of Directors.

The Board of Directors proposes re-election of the following board members elected by the Annual General Meeting: Göran Ando (chairman), Jeppe Christiansen (vice chairman), Brian Daniels, Sylvie Grégoire, Liz Hewitt and Mary Szela.

The Board of Directors proposes election of Kasim Kutay and Helge Lund as new members of the Board of Directors at the Annual General Meeting.

Mr Kutay is chief executive officer of Novo A/S, Denmark. The Board of Directors recommends election of Mr Kutay primarily because of his extensive experience as
financial advisor to the pharmaceutical, biotechnology and medical device industries. Furthermore, Mr Kutay has advised healthcare companies on an international basis including companies based in Europe, the USA, Japan and India.

Mr Lund is former chief executive officer of the integrated gas company, BG Group plc. The Board of Directors recommends election of Mr Lund primarily because of his extensive executive and board experience in large multinational companies headquartered in Scandinavia within regulated markets and significant financial knowledge.

Further information
Media:
Katrine Sperling +45 4442 6718 krsp@novonordisk.com (mailto:krsp@novonordisk.com)
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com (mailto:kiau@novonordisk.com)
 

Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com (mailto:phak@novonordisk.com)
Hanna Ögren   +45 3079 8519 haoe@novonordisk.com (mailto:haoe@novonordisk.com)
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com (mailto:armk@novonordisk.com)
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com (mailto:kpvj@novonordisk.com)

 

 Company announcement No 13 / 2017


PR170224_AGM_notice_total_UK (http://hugin.info/2013/R/2081567/784096.pdf)


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.